Background:

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Classification:

Primary antibody

Alternative names:

Von Hippel-Lindau disease tumor suppressor ;Protein G7;pVHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL

Species reactivity:

Human, Rat, Mouse

Host:

Rabbit

Isotype:

IgG

Immunogen:

The antiserum was produced against synthesized peptide derived from the N-terminal region of human VHL. AA range:1-50

Concentration:

1 mg/ml

Molecular weight:

Applications:

IHC-p, IF, ELISA

Storage:

-20°C for 1 year

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com